Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer

INTRODUCTION: The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to cause mineralocorticoid excess syndrome characteri...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Case Rep Urol
Auteurs principaux: Yamamoto, Yutaka, Akashi, Yasunori, Minami, Takahumi, Nozawa, Masahiro, Kiba, Keisuke, Yoshikawa, Motokiyo, Hirayama, Akihide, Uemura, Hirotsugu
Format: Artigo
Langue:Inglês
Publié: Hindawi 2018
Sujets:
Case Report
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6165612/
https://ncbi.nlm.nih.gov/pubmed/30305978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/1414395
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires